IP Library Granted Patent US 10,874,092
Granted Patent B2
US 10,874,092 · App. 15/739,042 · Granted Dec 29, 2020

Humanized skeletal muscle

Inventors: Daniel J. Garry (Eagan, MN); Mary G. Garry (Eagan, MN); Naoko Koyano (Shoreview, MN)
Assignee: Regents of the University of Minnesota
A01K67/0271A01K67/0276C12N5/0604C12N5/0658A01K2217/00A01K2217/075A01K2217/15A01K2227/108A01K2267/025A61K35/34C12N2510/00C12N2517/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,092
App. No.
15/739,042
Granted
Dec 29, 2020
Kind
B2
Abstract

Described herein is a method for producing a chimeric non-human animal expressing a human a MYF5, MYOD, MRF4 gene or a combination thereof gene comprising: a) generating an MYF5, MYOD, MRF4 or combination thereof null non-human animal cell, wherein both copies of the non-human MYF5, MYOD, MRF4 gene or combination thereof carry a mutation that prevents production of functional MYF5, MYOD, MRF4 protein or combination thereof in said non-human animal; b) creating a MYF5, MYOD, MRF4 or combination thereof null non-human blastocyst by somatic cell nuclear transfer comprising fusing a nucleus from said MYF5, MYOD, MRF4 or combination thereof null non-human animal cell of a) into an enucleated non-human oocyte and activating said oocyte to divide so as to form an MYF5, MYOD, MRF4 or combination thereof null non-human blastocyst; c) introducing human stem cells into the MYF5, MYOD, MRF4 or combination null non-human blastocyst of b); and d) implanting said blastocyst from c) into a pseudopregnant surrogate non-human animal to generate a chimeric non-human animal expressing human MYF5, MYOD, MRF4 or combination thereof.

Claims (2)

1. A chimeric pig embryo comprising: (i) homozygous disruptions of endogenous MYF5, MYOD, and MRF4 genes in it genome, wherein said disruptions result in no expression of the endogenous MYF5, MOYD, and MRF4 proteins; and (ii) human skeletal muscle cells expressing human MYF5, MYOD, and MRF4 proteins, wherein the human skeletal muscle cells are differentiated from human pluripotent stem cells introduced into a pig embryo at an earlier stage of development than said chimeric pig embryo and wherein the introduced human pluripotent cells integrated into the inner cell mass of the pig embryo at the blastocyst stage.

2. A chimeric pig blastocyst comprising: (i) homozygous disruptions of endogenous MYF5, MYOD, and MYF4 genes in its genome, wherein said disruptions result in no expression of the endogenous MYF5, MOYD, and MRF4 proteins; and (ii) human pluripotent cells having intact MYF5, MYOD, and MRF4 genes, wherein the human pluripotent cells integrate into the inner cell mass of the blastocyst.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2020
From: GARRY, DANIEL J.; GARRY, MARY G.; KOYANO, NAOKO
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 053526/0242 →
Continuity (2)
Provisional Application 62187027 · Jun 30, 2015
Related Publication 20180177166A1 · Jun 28, 2018